The doses of cuproptosis-inducing agents that mediated cuproptosis, as indicated by decreased FDX1 expression, were higher for normal astrocytes than for GBM cells, suggesting that GBM cells may be more sensitive than astrocytes to cuproptosis-inducing drugs. The gene discussed is FDX1; the disease is glioblastoma.